Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: Effect of TMPRSS2 Met160Val

BJU International

Volumn 107, Issue 3, 2011, Pages 466-470

  Giri, Veda N ^a   Ruth, Karen ^a   Hughes, Lucinda ^a   Uzzo, Robert G ^a   Chen, David Y T ^a   Boorjian, Stephen A ^a   Viterbo, Rosalia ^a   Rebbeck, Timothy R ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

genetics; prostate; prostatic neoplasms; risk assessment; screening

Indexed keywords

METHIONINE; PROSTATE SPECIFIC ANTIGEN; VALINE;

ADULT; AFRICAN AMERICAN; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRCA2 GENE; CANCER SCREENING; CAUCASIAN; CONTROLLED STUDY; FAMILY HISTORY; FOLLOW UP; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENOTYPE; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MALE; ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RACE DIFFERENCE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSMEMBRANE SERINE PROTEASE 2 GENE;

ADULT; AGED; BIOPSY; EARLY DETECTION OF CANCER; EPIDEMIOLOGIC METHODS; ETHNIC GROUPS; GENE FREQUENCY; GENETIC TESTING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MASS SCREENING; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; POLYMORPHISM, GENETIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 79251552551     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09522.x     Document Type: Article

References (20)

1. American Cancer Society. Cancer Facts and Figures 2009. Atlanta: American Cancer Society, 2009: Available from URL:. Accessed July 2009
2. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
3. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
4. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802
5. Catalona WJ, Antenor JA, Roehl KA, Moul JW,. Screening for prostate cancer in high risk populations. J Urol 2002; 168: 1980-3
6. Giri VN, Beebe-Dimmer J, Buyyounouski M, et al. Prostate cancer risk assessment program: A 10-year update of cancer detection. J Urol 2007; 178: 1920-4
7. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8
8. Petrovics G, Liu A, Shahaduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847-52
9. Lin B, Ferguson C, White JT, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999; 59: 4180-4
10. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007; 60: 1238-43
11. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007; 97: 1690-5
12. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27: 253-63
13. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008; 8: 230
14. Bruner DW, Baffoe-Bonnie A, Miller S, et al. Prostate cancer risk assessment program. A model for the early detection of prostate cancer. Oncology (Williston Park) 1999; 13: 325-34
15. Kim SY, Park D, Oh M, Sellamuthu S, Park WJ,. Detection of site-specific proteolysis in secretory pathways. Biochem Biophys Res Commun 2002; 296: 419-24
16. Lubieniecka JM, Cheteri MK, Stanford JL, Ostrander EA,. Met160Val polymorphism in the TRMPSS2 gene and risk of prostate cancer in a population-based case-control study. Prostate 2004; 59: 357-9
17. Nwosu V, Carpten J, Trent JM, Sheridan R,. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet 2001; 10: 2313-8
18. Savage SA, Greene MH,. The evidence for prostate cancer risk loci at 8q24 grows stronger. J Natl Cancer Inst 2007; 99: 1499-501
19. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-9
20. Salinas CA, Koopmeiners JS, Kwon EM, et al. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009; 69: 363-72